← Leaderboards
Victoria P Werth
Philadelphia Va Medical Center
$5,101,932
Attributed
$9,436,509
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,436,509 · 7
VA$0 · 3
By mechanism
UC2$5,148,251 · 1
R01$2,340,542 · 2
K24$1,265,404 · 1
R21$387,200 · 1
R41$293,749 · 1
M01$1,363 · 1
Top collaborators
- Jill P Buyon6 shared
- Michelle A Petri6 shared
- Brad H Rovin6 shared
- Benjamin Franklin Chong3 shared
- Andrew R Draganski2 shared
- Rudolph C Johnson1 shared
Others in their field
Top investigators on “Cutaneous”
- Donald Ym Leung · University Of Colorado Denver$38,268,863
- David Leung · National Jewish Health$31,859,607
- David Wofsy · University Of California, San Francisco$31,423,453
- Louis D Falo · University Of Pittsburgh At Pittsburgh$26,553,342
- Wilhelmus G. J. Hol · University Of Washington$25,259,933
- Robert L Modlin · University Of California Los Angeles$23,943,503
Research focus
CutaneousSkinCellsLupusAutoimmune DiseasesResponseSkin DisorderImmuneSeveritiesQuality Of LifeAreaMolecularMediatingProgramsInflammatoryTissuesBiopsyPathway InteractionsInflammationPennsylvaniaSamplingClinical TrialsAcuteUniversities
Grant awards (36)
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$1,249,871
UC2 · FY2025 · AR
Extracellular vesicles as a novel mediator for ultraviolet-B light induced photoaging and skin inflammation.$0
I01 · FY2025 · VA · contact PI
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$600,000
UC2 · FY2024 · AR
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$288,149
UC2 · FY2024 · AR
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.$145,888
R41 · FY2024 · AR
Extracellular vesicles as a novel mediator for ultraviolet-B light induced photoaging and skin inflammation.$0
I01 · FY2024 · VA · contact PI
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$1,600,000
UC2 · FY2023 · AR
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis$402,425
R01 · FY2023 · AR · contact PI
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT) - Pain Supplement$356,561
UC2 · FY2023 · AR
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.$147,861
R41 · FY2023 · AR
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$1,053,670
UC2 · FY2022 · AR
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis$401,824
R01 · FY2022 · AR · contact PI
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis$48,448
R01 · FY2022 · AR · contact PI
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis$407,138
R01 · FY2021 · AR · contact PI
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis$427,678
R01 · FY2020 · AR · contact PI
Optimization of Clinical Trial Design in Cutaneous Lupus$213,107
R01 · FY2020 · AR
Optimization of Clinical Trial Design in Cutaneous Lupus$213,141
R01 · FY2019 · AR
Optimization of Clinical Trial Design in Cutaneous Lupus$226,781
R01 · FY2018 · AR
Treatment of Dermatomyositis with Ajulemic Acid, a Non-Psychoactive Cannabinoid$211,200
R21 · FY2016 · AR · contact PI
Request for a CyTOF Helios System$0
IS1 · FY2016 · VA · contact PI
The role of TNF-Alpha in cutaneous integrity$0
I01 · FY2016 · VA · contact PI
The role of TNF-Alpha in cutaneous integrity$0
I01 · FY2015 · VA · contact PI
Treatment of Dermatomyositis with Ajulemic Acid, a Non-Psychoactive Cannabinoid$176,000
R21 · FY2014 · AR · contact PI
The role of TNF-Alpha in cutaneous integrity$0
I01 · FY2014 · VA · contact PI
The role of TNF-Alpha in cutaneous integrity$0
I01 · FY2013 · VA · contact PI
Patient-oriented research in skin autoimmune disease$153,485
K24 · FY2012 · AR · contact PI
Patient-oriented research in skin autoimmune disease$153,485
K24 · FY2011 · AR · contact PI
Patient-oriented research in skin autoimmune disease$150,588
K24 · FY2010 · AR · contact PI
Patient-oriented research in skin autoimmune disease$147,773
K24 · FY2009 · AR · contact PI
Patient-oriented research in skin autoimmune disease$145,042
K24 · FY2008 · AR · contact PI
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE$109,185
K24 · FY2005 · AR
ASSESS THE SAFETY OF PI-0824 IN PATIENTS WITH PEMPHIGUS VULGARIS$1,363
M01 · FY2005 · RR
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE$106,004
K24 · FY2004 · AR
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE$102,916
K24 · FY2003 · AR
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE$99,918
K24 · FY2002 · AR
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE$97,008
K24 · FY2001 · AR